| Literature DB >> 19858489 |
Manran Liu1, Mathew C Casimiro, Chenguang Wang, L Andrew Shirley, Xuanmao Jiao, Sanjay Katiyar, Xiaoming Ju, Zhiping Li, Zuoren Yu, Jie Zhou, Michael Johnson, Paolo Fortina, Terry Hyslop, Jolene J Windle, Richard G Pestell.
Abstract
p21(CIP1/WAF1) is a downstream effector of tumor suppressors and functions as a cyclin-dependent kinase inhibitor to block cellular proliferation. Breast tumors may derive from self-renewing tumor-initiating cells (BT-ICs), which contribute to tumor progression, recurrence, and therapy resistance. The role of p21(CIP1) in regulating features of tumor stem cells in vivo is unknown. Herein, deletion of p21(CIP1), which enhanced the rate of tumorigenesis induced by mammary-targeted Ha-Ras or c-Myc, enhanced gene expression profiles and immunohistochemical features of epithelial mesenchymal transition (EMT) and putative cancer stem cells in vivo. Silencing of p21(CIP1) enhanced, and expression of p21(CIP1) repressed, features of EMT in transformed immortal human MEC lines. p21(CIP1) attenuated oncogene-induced BT-IC and mammosphere formation. Thus, the in vitro cell culture assays reflect the changes observed in vivo in transgenic mice. These findings establish a link between the loss of p21(CIP1) and the acquisition of breast cancer EMT and stem cell properties in vivo.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19858489 PMCID: PMC2776463 DOI: 10.1073/pnas.0910009106
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205